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It has been proposed that PPAR-dependent, accelerated catabolism of proinﬂammatory mediators may contribute to the fast
resolution of inﬂammation. Because retinoid X receptors are obligate heterodimer partners of PPARs, we investigated the impact
of deleting hepatocyte-speciﬁc RXRα on the antiedema eﬀect of PPAR agonists. In wild-type mice (WT), pretreatment with the
PPARα agonist perﬂuorooctanoic acid diminished carrageenan-induced paw edema by 66±10%. This eﬀect was essentially absent
(13 ± 8%) in hepatocyte-speciﬁc RXRα-deﬁcient mice. Similarly, pretreatment of WT mice with the PPARδ agonist L-783483 or
thePPARγ agonist L-805645 caused 54±1% and38±8% reductionincarrageenan-induced pawedema, respectively. Theseeﬀects
were also signiﬁcantly diminished or absent in hepatocyte-speciﬁc RXRα-deﬁcient mice. In contrast, aspirin reduced carrageenan-
induced paw edema equally in WT and hepatocyte-speciﬁc RXRα-deﬁcient mice. The identiﬁcation of RXRα as an important
factor involved in the antiedema eﬀect produced by agonists of the three PPAR subtypes is a signiﬁcant achievement towards the
goal of designing novel, eﬀective anti-inﬂammatory drugs.
Copyright © 2006 Y.-J. Y. Wan and M. Z. Badr. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
I th a sb e e nr e p o r t e db yu s[ 1–3], as well as by others [4–6]
that agonists of the peroxisome proliferator-activated recep-
tors (PPARs) diminish inﬂammatory responses. In attempt-
ing to delineate mechanisms involved in this eﬀect, it was
proposedamongvariousotherpostulatesthatterminationof
the biological activity of proinﬂammatory mediators might
occur in the liver via PPAR-dependent catabolic pathways
[4]. These pathways are known to be augmented following
exposure to PPAR agonists, particularly those which activate
PPARα [4].
Retinoid X receptor alpha (RXRα)i sr e p o r t e dt op l a ya
central role in mediating PPAR-induced eﬀects [7–9], and
the expression of both PPARs and RXRs decreases in tissues,
including the liver of animal models of inﬂammation [10].
Therefore, we hypothesized that the absence of hepatocyte-
speciﬁc RXRα shall interfere with the ability of PPAR ago-
nists to control inﬂammation. Using the intraplantar injec-
tion of carrageenan as a well-established in vivo model of in-
ﬂammation, the present experiments were designed to eval-
uate the anti-inﬂammatory eﬀect of subtype-selective PPAR
ligands in hepatocyte-speciﬁc RXRα-deﬁcient mice. Results
show that hepatocytic RXRα plays an important role in me-
diatingthePPAR-inducedameliorationofcutaneousinﬂam-
mation. We postulate that the hepatocyte-speciﬁc RXRα is
involved in enhancing the metabolic removal of proinﬂam-
matory mediators and/or increasing the production of anti-
inﬂammatory mediators in the liver.
The identiﬁcation of a speciﬁc receptor subtype (RXRα)
in a speciﬁc cell population (hepatocytes) may prove instru-
mental in the pursuit to fully elucidate mechanisms involved
in the antiinﬂammatory eﬀect of PPAR agonists, as well as




Male hepatocyte-speciﬁc RXRα-deﬁcient mice were pro-
d u c e da sr e p o r t e dp r e v i o u s l y[ 9]. Animals were cared for in
accordance to the guidelines set forth by the National In-


























Figure 1: Carrageenan-induced paw edema in hepatocyte-speciﬁc
RXRα-deﬁcient mice. Wild-type and hepatocyte-speciﬁc RXRα-
deﬁcient mice were treated with 30μLo f1 %c a r r a g e e n a ni nn o r -
mal saline subcutaneously into the midplantar region of the right
hindpaw. Carrageenan-induced edema, reﬂected as an increase in
dorsal-to-ventral paw thickness, was measured with a microcaliper.
Values represent mean ±SEM. n = 8m i c ep e rg r o u p .
of laboratory animals. All experiments were approved by
the University of Missouri–Kansas City Institutional Animal
Care and Use Committee.
Carrageenan (type IV, lambda) was obtained from Fluka
(Milwaukee, WI), while aspirin and perﬂuorooctanoic acid
were from Sigma Aldrich (St Louis, MO). The PPARγ ago-
nist L-805645 and PPARδ agonist L-738483 were provided
by Merck (Rahway, NJ).
Animaltreatment
Tested compounds (200μL in normal saline at a dose of
100mg/kg), or the saline vehicle, was administered in-
traperitoneally to wild-type and hepatocyte-speciﬁc RXRα-
deﬁcient mice. Since we previously observed that PPAR ago-
nists equally diminished inﬂammation when given 30 min-
utes prior to, or 90 minutes after the induction of paw edema
[1], we limited the present study to the 30 minute pre-
carrageenan injection of PPAR agonists. Carrageenan (30μL
of 1% in normal saline), or an equivalent volume of saline,
was subcutaneously injected into the midplantar region of
the right hindpaw. Carrageenan-induced edema, reﬂected as
an increase in dorsal-to-ventral paw thickness, was measured
with a microcaliper (Mitutoyo Corp; Kanagawa, Japan). The
averageof3measurementsateachtime-pointwascalculated.
Dataanalysisandstatistics
Carrageenan-evoked edema responses were analyzed by Stu-
dent’s t test (Figures 1 and 6), or ANOVA (Figures 2–5).
























































Figure 2: Eﬀect of the PPARα agonist perﬂuorooctanoic acid (PFOA)
on the temporal proﬁle of carrageenan-induced paw edema in wild-
type and hepatocyte-speciﬁc RXRα-deﬁcient mice. Wild-type (A) and
hepatocyte-speciﬁcRXRα-deﬁcientmice(B)weretreatedintraperi-
toneally with (100mg/kg) of PFOA, 30 minutes before induction
of inﬂammation. As indicated by the arrow, carrageenan (1%, in-
traplantar) was injected at t = 0. Carrageenan-induced edema is
reﬂected by an increase in paw thickness. Values represent mean





As illustrated in Figure 1, intraplantar injection of car-
rageenan in wild-type mice increased paw thickness, with
a peak at approximately 1hr post-injection. The maximalY.-J. Y. Wan and M. Z. Badr 3























































Figure 3: Antiedema eﬀect of the PPARδ agonist L-738483 on carrageenan-induced paw edema in wild-type and hepatocyte-speciﬁc RXRα-
deﬁcient mice. Wild-type (a) and hepatocyte-speciﬁc RXRα-deﬁcient mice (b) were treated intraperitoneally with (100mg/kg) of L-738484,
30 minutes before induction of inﬂammation. As indicated by the arrow, carrageenan (1%, intraplantar) was injected at t = 0. Carrageenan-
induced edema is reﬂected by an increase in paw thickness. Values represent mean ±SEM. n = 3–5 mice per group. ∗P<. 05 versus
corresponding wild-type point.
increase in paw thickness was 35% over basal values, and
lasted through the 4hr duration of the experiment. Mice
lacking hepatocyte-speciﬁc RXRα also showed a comparable
increase and trend in paw thickness in response to intraplan-
tar carrageenan injection (Figure 1).
AntiedemaeffectofPPARagonistsin
hepatocyte-speciﬁcRXRα-deﬁcientmice
In wild-type mice, pretreatment with 100mg/kg of the
PPARα agonist perﬂuorooctanoic acid (PFOA) diminished
carrageenan-induced paw edema by 66 ± 10% 2–4h fol-
lowing carrageenan injection (Figures 2(a) and 6). This ef-
fect was essentially absent (13 ± 8%) in hepatocyte-speciﬁc
RXRα-deﬁcient mice (Figures 2(b) and 6). Similarly, pre-
treatment of wild-type mice with similar doses of either of
thePPARδ agonistL-783483,orthePPARγ agonistL-805645
caused 54 ± 1% and 38 ± 8% reduction in carrageenan-
induced paw edema, respectively (Figures 3(a), 4(a),a n d6).
These eﬀects were signiﬁcantly lower (30 ± 6%) or absent
(8±5%) in hepatocyte-speciﬁc RXRα deﬁcient mice, respec-
tively (Figures 3(b), 4(b),a n d6). Conversely, aspirin which
is a known inhibitor of the cyclooxygenase enzyme, reduced
carrageenan-induced paw edema equally in wild-type and
hepatocyte-speciﬁc RXRα-deﬁcient mice (Figures 5 and 6).
The reduction in paw edema was 51±12% and 51±3% x in
these two groups of mice, respectively (Figure 6).
DISCUSSION
Retinoid X receptors (RXR) play a central role as obli-
gate heterodimer partners for numerous nuclear receptors,
including PPARs [7]; thereby serving as master regulators
of crucial pathways [7]. The RXR/PPAR heterodimer is ac-
tivated by agonists of either RXR or PPAR, leading to the
activation of speciﬁc pathways [8], with the combination of
RXRandPPARagonistscausingagreatereﬀectthanagonists
of either receptor alone [8]. Genetic deletion of hepatocyte-
speciﬁc RXRα drastically, albeit not completely, interfered
with PPAR-mediated pathways [9, 10]. In light of these facts,
this study was pursued to take advantage of the availability
of mice lacking hepatocyte RXRα to investigate potential role
played by the liver in the antiedema eﬀect ascribed to PPAR
agonists.
Our data clearly show that the absence of hepatocyte-
speciﬁc RXRα signiﬁcantly diminished the ability of ago-
nists of PPARα,P P A R δ,a n dP P A R γ to exert antiedema ef-
fect in vivo, while exhibiting no eﬀect on aspirin-induced
antiedema (Figures 2–6). A previous study concluded that
activation of PPARα hastened the catabolic termination of
the inﬂammatory response to leukotriene B4 [4]. In support
of this conclusion, preliminary experiments by the same au-
thors showed diminished plasma clearance of leukotriene B4
in PPARα-deﬁcient mice, as compared to wild-type mice [4].
It should be noted however that in contrast to the beneﬁcial
eﬀect of PPARα agonists in controlling inﬂammatory pro-
cesses, published reports present evidence for a proinﬂam-
matory response to these agonists; an eﬀect that is explained
by potential diﬀerences in cell- and/or tissue-speciﬁc suscep-
tibility [11].
PPARγ agonists have been shown to interfere with nu-
merous pathways involved in the inﬂammatory process, in
the course of exerting their reported anti-inﬂammatory ac-
tivity [11]. However, whether agonists of PPARγ and/or4 PPAR Research























































Figure 4: Eﬀect of the PPARγ agonist L-805645 on the proﬁle of
carrageenan-induced paw edema in wild-type and hepatocyte-speciﬁc
RXRα-deﬁcient mice. Wild-type (a) and hepatocyte-speciﬁc RXRα-
deﬁcient mice (b) were treated intraperitoneally with (100mg/kg)
of L-805645, 30 minutes before induction of inﬂammation. As in-
dicated by the arrow, carrageenan (1%, intraplantar) was injected
at t = 0. Carrageenan-induced edema is reﬂected by an increase
in paw thickness. Values represent mean ±SEM. n = 4–6 mice per
group. ∗P<. 05 versus corresponding wild-type point.
PPARδ recruit the hepatic metabolic machinery to control
inﬂammation is not reported in the literature. Thus, this
is the ﬁrst report, to our knowledge, that presents an ev-
idence for a unifying mechanism involving the liver, ex-
plaining the anti-inﬂammatory eﬀect of agonists of the three
known PPAR subtypes.
























































Figure 5: Eﬀect of aspirin on carrageenan-induced paw edema in
wild-typeandhepatocyte-speciﬁcRXRα-deﬁcientmice.Wild-type (a)
and hepatocyte-speciﬁc RXRα-deﬁcient mice (b) were treated in-
traperitoneallywith(50mg/kg)ofaspirin,30minutesbeforeinduc-
tion of inﬂammation. As indicated by the arrow, carrageenan (1%,
intraplantar) was injected at t = 0. Carrageenan-induced edema
is reﬂected by an increase in paw thickness. Values represent mean
±SEM. n = 3–5 mice per group. ∗P<. 05 versus corresponding
wild-type point.
The speciﬁc requirement for RXRα by all PPAR sub-
types, observed in this study, may be explained by the fact
that this receptor is a heterodimer partner of the three PPAR
subtypes. The absence of RXRα is consequently expected to
hinder the activation of pathways controlled by agonists se-






























































































Figure 6: Percent inhibition of paw edema by various PPAR agonists
and aspirin in wild-type (a) and hepatocyte-speciﬁc RXRα-deﬁcient
(b) mice. D a t as h o w ni nF i g u r e s2–5 above are expressed as the per-
centage change in paw edema relative to control group 2–4h after
carrageean injection. Values represent mean ±SEM. N = 3–6 mice
per group. ∗P<. 05 versus corresponding wild-type group.
explain the residual anti-inﬂammatory eﬀect of PPAR ago-
nists observed in hepatocyte-speciﬁc RXRα-deﬁcient mice,
we propose the following. (1) It is noteworthy that these
agonists have been shown to produce eﬀects that are not
PPAR-dependent [12–16]. This is an unlikely explanation
however in light of the fact that preliminary experiments in
our laboratories reveal that PPARα plays a signiﬁcant role in
mediating the anti-inﬂammatory eﬀect of its agonists (not
shown). (2) Another possibility that may explain the resid-
ual anti-inﬂammatory eﬀect of PPAR agonists observed in
hepatocyte-speciﬁc RXRα-deﬁcient mice takes into consid-
erations the fact that these mice retain the ability to express
RXRβ and RXRγ in hepatocytes [9, 10]. Both of these recep-
torsubtypesmayactasheterodimerpartnersofPPARsinthe
absence of RXRα [9, 10]. (3) Since our animal model lacks
RXRα exclusively in hepatocytes [10], RXRα present in liver
cell types other than hepatocytes may contribute to the par-
tial anti-inﬂammatory eﬀect of PPAR agonists observed in
these mice. (4) Lastly, whether there are PPAR-mediated ef-
fects that are not fully dependent on the heterodimerization
of these receptors with RXRs is an interesting postulate that
deserves evaluation.
In conclusion, data presented here show that hepatic
events involving RXRα are crucial to the antiedema eﬀect
of PPAR agonists. These eﬀects may include acceleration of
themetabolicremovalofproinﬂammatorymediatorsand/or
enhanced production of antiinﬂammatory mediators in the
liver. Identifying hepatocyte-speciﬁc RXRα as a crucial link
in the mechanism by which PPAR agonists produce anti-
inﬂammatory eﬀect is indeed a signiﬁcant ﬁrst step to-
wards fully deﬁning molecular events involved in this ac-
tion, as well as designing novel, eﬀective anti-inﬂammatory
drugs.
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